GB9401460D0 — Compositions of matter
Assigned to Rhone Poulenc Rorer Ltd · Expires 1994-03-23 · 32y expired
What this patent protects
This invention is directed to compounds of formula (I), wherein R<1> is an optionally substituted lower alkyl group; R<2> is an optionally substituted oxaaliphatic group; R<3> is an optionally substituted aryl group or an optionally substituted heteroaryl group;…
USPTO Abstract
This invention is directed to compounds of formula (I), wherein R<1> is an optionally substituted lower alkyl group; R<2> is an optionally substituted oxaaliphatic group; R<3> is an optionally substituted aryl group or an optionally substituted heteroaryl group; Q<1>, Q<2> and Q<3> are independently nitrogen, CX or CH; Z<1> is oxygen or sulfur; Z<2> is -CH=CH-, -CC-, -CH2-CZ-, -CZCH2-, -CZ-CZ-, -CH2-NH-, -CH2-O-, -CH2-S-, -CX2-O-, -CZNH-, -NH-CH2-, -O-CH2_, -SCH2-, -SOCH2-, -SO2CH2-, -O-CX2-, -O-CZ-, -NH-CZ-, -N=N-, -NH-SO2-, -SO2-NH-, -CZ-CZ-NH-, -NH-CO-O-, -O-CO-NH- or -NH-CO-NH-; Z is oxygen or sulfur; and X is halo; or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which possess useful pharmaceutical properties. They are especially useful for inhibiting the production or physiological effects of TNF and inhibit cyclic AMP. The present invention is also directed to their pharmaceutical use, pharmaceutical compositions containing the compounds, and methods for their preparation.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.